We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $142M
1-Year Est. Return 783.79%
This Fund
S&P 500
This Quarter Est. Return
+21.43%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$277M
AUM Growth
-$90.1M
Cap. Flow
-$75.2M
Cap. Flow %
-27.11%
Top 10 Hldgs %
45.56%
Holding
64
New
13
Increased
10
Reduced
20
Closed
18

Top Buys

Rank Stock Value
1
VTGN icon
VistaGen Therapeutics
VTGN
+$10.7M
2
VINC
Vincerx Pharma, Inc. Common Stock
VINC
+$7.95M
3
EPIX
ESSA Pharma
EPIX
+$6.67M
4
CMRX
Chimerix, Inc.
CMRX
+$6.5M
5
ACRS icon
Aclaris Therapeutics
ACRS
+$6.21M

Top Sells

Rank Stock Value
1
LRMR icon
Larimar Therapeutics
LRMR
+$18.5M
2
CLDX icon
Celldex Therapeutics
CLDX
+$14M
3
IMVT icon
Immunovant
IMVT
+$13.1M
4
SAGE
Sage Therapeutics
SAGE
+$11.3M
5
CMPS
Compass Pathways
CMPS
+$10M

Sector Composition

Rank Sector Weight
1 Healthcare 91.38%
2 Financials 5.21%
3 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BGMS
51
Bio Green Med Solution Inc
BGMS
$5.24M
– –
-42
Closed -$1.17M
IMVT icon
52
Immunovant
IMVT
$8.25B
– –
-283,500
Closed -$13.1M
LRMR icon
53
Larimar Therapeutics
LRMR
$432M
– –
-863,100
Closed -$18.5M
MDGL icon
54
Madrigal Pharmaceuticals
MDGL
$11.8B
– –
-32,500
Closed -$3.61M
RCKT icon
55
Rocket Pharmaceuticals
RCKT
$394M
– –
-20,000
Closed -$1.1M
REPL icon
56
Replimune Group
REPL
$1.01B
– –
-207,500
Closed -$7.92M
RLMD icon
57
Relmada Therapeutics
RLMD
$519M
– –
-120,000
Closed -$3.85M
WVE icon
58
Wave Life Sciences
WVE
$1.2B
– –
-107,500
Closed -$846K
KRTX
59
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
– –
-5,000
Closed -$508K
SURF
60
DELISTED
Surface Oncology, Inc. Common Stock
SURF
– –
-999,500
Closed -$9.23M
ONCR
61
DELISTED
Oncorus, Inc.
ONCR
– –
-53,500
Closed -$1.73M
CNCE
62
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
– –
-537,500
Closed -$6.79M
PANA.WS
63
DELISTED
Panacea Acquisition Corp. Redeemable warrants, each whole warrant exercisable for one share of Class
PANA.WS
– –
-93,332
Closed -$299K
BHVN
64
CALL
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
– –
-50,000
Closed -$4.29M
1 2
3

Similar funds

EC
EJF Capital Arlington, Virginia $142M AUM 23.3% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
POIA
Pin Oak Investment Advisors Houston, Texas $141M AUM 20.83% 1-Year Est. Return
TM
TFJ Management Somerville, Massachusetts $141M AUM 9.28% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $141M AUM

Acuta Capital Partners's Q1 2021 Portfolio in Review

As of Q1 2021, Acuta Capital Partners held 64 positions worth $277M, down 25% from $367M the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Acuta Capital Partners withdrew a net $75.2M in Q1 2021, closing 18 positions and reducing 20 holdings. Its most notable exit was Larimar Therapeutics, an estimated $18.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, up from 89% a quarter earlier, followed by Financials and Industrials.

Against the trend, Acuta Capital Partners opened a new position in Vincerx Pharma, Inc. Common Stock worth $7.6M.

  • Acuta Capital Partners's largest Q1 2021 buy was Vincerx Pharma, Inc. Common Stock: 19,700 shares worth $7.6M.
  • Acuta Capital Partners added most to VistaGen Therapeutics in Q1 2021, an estimated $10.7M increase.
  • Acuta Capital Partners's biggest Q1 2021 reduction was Celldex Therapeutics, cutting an estimated $14M.
  • Acuta Capital Partners fully exited Larimar Therapeutics in Q1 2021, selling an estimated $18.5M.
  • Acuta Capital Partners's ten largest holdings make up 46% of its $277M portfolio in Q1 2021.
  • Acuta Capital Partners opened 13 new positions and closed 18 in Q1 2021.
  • Acuta Capital Partners's portfolio value fell 25% quarter-over-quarter to $277M.

Based on Acuta Capital Partners's 13F filing for Q1 2021, filed 17 May 2021.